

News Release

12 December 2013

All Wales Medicine Strategy Group recommends the use of Ameluz®

Leverkusen, Germany – Biofrontera AG (DSE: B8F) announces that the Health Minister in Wales, UK, has issued a recommendation on the use of Biofrontera's Ameluz® in photodynamic therapy (PDT) of actinic keratoses based on a recommendation of the Welsh Health Authority .

The All Wales Medicine Strategy Group (AWMSG) is responsible for evaluating the clinical and cost effectiveness of medications to be used in the National Health Service in Wales. The recommendation for the use of Ameluz® was based on a proposal of the company, in which the clinical efficacy and the cost-effectiveness of the use of Ameluz® were compared to the competing product Metvix®. The Authority has explicitly confirmed the conclusions of the company's pharmaco-economic report.

This decision confirms the statement of the Scottish Health Authority, the Scottish Medicines Consortium (SMC), who, in December last year, accepted Ameluz® for use in the Scottish National Health Service (cf. press release: December 17, 2012). The positive vote of the AWMSG even goes a step further by recommending Ameluz® against Metvix®, if a photodynamic therapy (PDT) is appropriate.

The detailed documentation of the AWMSG is available on the Authority's website under the search item "Ameluz": <http://www.awmsg.org>.

Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG, commented: "The strong recommendation of the Welsh Authority, which confirms the previous economic evaluation of the Scottish authority, is an important step to promote the marketing of Ameluz® in the UK. The underlying pharmaco-economic analysis has a great impact also on other European markets, since it illustrates the cost efficiency of PDT with Ameluz® compared to other treatment options. Despite the higher short-term treatment costs related to a PDT in comparison to other treatment options, the health care systems will save money long-term."

For further information please contact:

Anke zur Mühlen
Corporate Communication

+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen@biofrontera.com

Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany

News Release

About Biofrontera

Biofrontera Pharma GmbH is a wholly-owned subsidiary of Biofrontera AG. The Biofrontera group aims at attending and treating the skin, recognizing the aesthetic needs of a person's visual reflection.

Biofrontera is listed at the regulated market of the Frankfurt stock exchange under the symbol B8F and the ISIN number DE0006046113. www.biofrontera.com

This press release contains forward-looking statements based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the assumptions expressed or implied in this press release to be faulty. Given these risks, uncertainties and other factors, recipients of this document are cautioned not to place undue reliance on the forward-looking statements. Biofrontera AG disclaims any obligation to update these forward-looking statements to reflect future events or developments.

References:

- ¹ Mudigonda T et al. (2010) The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw 8: 888-96.
- ² Glogau RG (2000) The risk of progression to invasive disease. J Am Acad Dermatol 42: 23-4.
- ³ Szeimies RM et al. (2010) Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 163: 386-94.
- ⁴ Dirschka T et al. (2013) Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 168: 825-36.